Drug Profile
Research programme: atherosclerosis/dyslipidaemia/obesity/type 2 diabetes therapeutics - Genfit
Alternative Names: G 800; GFT 679; GFT-1229Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genfit
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Lipid metabolism disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in France
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in France
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in France